Novo Nordisk/Aradigm Inhaled Insulin Study For Type 1 Diabetes Raises Efficacy Concern
• By Lee Szilagyi
Clinical focus could shift solely to type 2 diabetes. Interim analysis shows unexpected delay in post-meal glucose suppression, but Novo and Aradigm say positive safety results make data “very usable in our regulatory filing.”
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Pink Sheet for daily insights
